UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-211719 ASHLAND INC. (a Delaware corporation) I.R.S. No. 81-2587835 8145 Blazer Drive Wilmington, Delaware 19808 Telephone Number ...

Ashland (ASH) Q3 2025 Earnings Call July 30, 2025 10:00 AM ET Company ParticipantsWilliam Whitaker - SVP & CFOGuillermo Novo - CEO & Chair of the BoardAlessandra Faccin Assis - SVP & General Manager - Life Sciences and IntermediatesJames Minicucci - SVP & GM - Personal CareDago Caceres - SVP & GM - Specialty AdditivesChristopher Parkinson - Managing DirectorDavid Begleiter - Managing DirectorJosh Spector - Executive Director - Chemicals Equity ResearchJohn Roberts - Managing DirectorConference Call Particip ...

Financial Data and Key Metrics Changes - Adjusted EBITDA was $113 million, down 19% year over year, or 10% excluding portfolio actions, driven by lower organic sales and production volume [7][15] - Sales for Q3 were $463 million, down 15% year over year, including a $53 million impact from portfolio optimization [14] - Adjusted EPS, excluding acquisition amortization, was $1.04, down 30% from the prior year [16] - Adjusted EBITDA margin was 24.4%, down 120 basis points [15] Business Line Data and Key Metrics Changes - Life Sciences sales were $162 million, down 17% year over year, primarily due to portfolio optimization initiatives [19] - Personal Care sales were $147 million, down 16% year over year, driven by portfolio optimization actions [25] - Specialty Additives sales declined 13% to $131 million, with organic sales and volumes both down 11% [30] - Intermediates generated $33 million in sales, down from $36 million in the same period last year [22] Market Data and Key Metrics Changes - Demand patterns remain mixed across the portfolio, with pharma steady and recovering, while personal care shows encouraging signs [42] - Specialty additives and intermediates are still facing headwinds, particularly in China [43] - Approximately 85% of the portfolio is tied to consumer end markets, many of which are non-cyclical and more resilient [11] Company Strategy and Development Direction - The company has completed its portfolio optimization and restructuring program, which remains ahead of schedule [12] - Focus on cost savings and operational discipline to support strong margins [6] - The company aims to drive differentiation and margin-accretive growth through innovation [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in long-term opportunities despite current mixed demand [42] - The company is monitoring regulatory developments and does not anticipate a material direct impact on fiscal year results from tariff-related uncertainties [44] - Management highlighted the importance of maintaining a disciplined capital allocation strategy while focusing on productivity and innovation [49] Other Important Information - The company generated nearly 100% free cash flow conversion in the quarter, demonstrating the strength of its underlying business [8] - Liquidity at quarter end was over $800 million, providing flexibility for strategic investments [17] Q&A Session Summary Question: Insights on fiscal year 2026 and market recovery - Management discussed the cleaner portfolio and stable demand expected in personal care and pharma, with potential upside in specialty additives depending on market conditions [54][56] Question: Clarification on cost savings and restructuring - Management confirmed that restructuring and network optimization actions are complete, with expected savings flowing through to the P&L [78][80] Question: Stability in personal care markets - Management noted stability in mass brands, while the prestige segment has shown variability, particularly in biofunctional actives [70][72] Question: Near-term sales guidance and segment performance - Management indicated expectations for a sales increase in Q4 driven by specific portfolio activities, particularly in personal care and pharma [95][98]

earnings conference call third quarter fiscal 2025 July 30, 2025 O Regulation G: Adjusted Results the information presented herein regarding certain uncudited adjusted results does not conform to generally accepted accounting principles in the United Srates (U.S. GAAP) should not be construed as an affernative to the reported results determined in accordance with U.S. GAAP. Ashland has included this non-GAAP information to assis in understranding the operating performance of the company ond its reportable s ...

Core Insights - Ashland (ASH) reported a revenue of $463 million for the quarter ended June 2025, reflecting a year-over-year decline of 14.9% and an EPS of $1.04 compared to $1.49 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $468.37 million by 1.15%, and the EPS was also below the consensus estimate of $1.15, resulting in a surprise of -9.57% [1] Revenue Breakdown - Revenue from Intermediates was $33 million, slightly below the average estimate of $34.81 million, marking a year-over-year decline of 8.3% [4] - Revenue from Specialty Additives reached $131 million, exceeding the estimated $123.73 million, but still represented a decline of 12.7% year-over-year [4] - Personal Care revenue was reported at $147 million, slightly above the estimate of $146.57 million, with a year-over-year decrease of 16% [4] - Life Sciences revenue was $162 million, below the average estimate of $169.65 million, showing a year-over-year decline of 16.9% [4] Adjusted EBITDA Performance - Adjusted EBITDA for Life Sciences was $54 million, slightly below the average estimate of $55.16 million [4] - Adjusted EBITDA for Intermediates was reported at $7 million, exceeding the average estimate of $3.48 million [4] - Adjusted EBITDA for Specialty Additives was $26 million, close to the average estimate of $26.25 million [4] - Adjusted EBITDA for Personal Care was $41 million, below the average estimate of $43.05 million [4] Stock Performance - Ashland's shares have returned +1.3% over the past month, underperforming the Zacks S&P 500 composite's +3.6% change [3] - The stock currently holds a Zacks Rank 5 (Strong Sell), indicating potential underperformance in the near term [3]

Ashland (ASH) came out with quarterly earnings of $1.04 per share, missing the Zacks Consensus Estimate of $1.15 per share. This compares to earnings of $1.49 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -9.57%. A quarter ago, it was expected that this chemical company would post earnings of $1.1 per share when it actually produced earnings of $0.99, delivering a surprise of -10%.Over the last four quarters, the company has ...

Exhibit 99.1 Ashland reports third quarter fiscal 2025 results and narrows full-year outlook range WILMINGTON, Del., July 29, 2025 – Ashland Inc. (NYSE: ASH) today announced financial results 1 for the third quarter of fiscal year 2025, which ended June 30, 2025, and narrows its full-year fiscal 2025 outlook range. Ashland, a global additives and specialty ingredients company, holds leadership positions in high-quality, consumer-focused markets including pharmaceuticals, personal care and architectural coat ...

Core Insights - Ashland Inc. reported third-quarter fiscal year 2025 results, with sales of $463 million, a 15% decrease from $544 million in the prior year, primarily due to Portfolio Optimization initiatives [2][4][22] - The company narrowed its full-year fiscal 2025 outlook, expecting sales between $1.825 billion and $1.850 billion and Adjusted EBITDA in the range of $400 million to $410 million [22][18] Financial Performance - Net loss totaled $742 million, down from net income of $6 million in the prior year, largely due to a non-cash goodwill impairment charge of $706 million [3][4] - Adjusted EBITDA was $113 million, a 19% decrease from $139 million in the prior year, with Portfolio Optimization contributing to a 9% decline [5][4] - Cash flows from operating activities were $114 million, a decrease from $128 million in the prior-year quarter [6][4] Segment Performance - Life Sciences segment sales were $162 million, down 17% year-over-year, primarily due to Portfolio Optimization initiatives [8][9] - Personal Care sales totaled $147 million, a 16% decrease compared to the prior year, impacted by customer-specific softness in biofunctional actives [10][11] - Specialty Additives sales were $131 million, down 13% from the prior year, with a notable decline in coatings sales in China [13][14] Strategic Initiatives - The company is focusing on cost savings and operational discipline to support strong margins amid mixed demand trends [2][18] - Ashland is implementing a $30 million restructuring program expected to generate approximately $7.5 million in savings in the fourth quarter [21][18] - The company is also advancing a $60 million manufacturing network optimization initiative to enhance operational efficiency [21][18] Market Outlook - The macroeconomic environment remains stable but subdued, with mixed demand trends across segments [18][22] - The company is seeing resilience in pharma, stability in Personal Care, and early signs of recovery in specific areas [23][18] - Ashland is benefiting from favorable foreign currency movements and stable raw material costs, which are expected to support margin performance [20][18]

WILMINGTON, Del., July 21, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) announced today that the board of directors has named William C. Whitaker, senior vice president and chief financial officer, Ashland, effective July 18, 2025. Whitaker has been serving as the company’s interim chief financial officer. Whitaker joined Ashland in 2015. He has held several positions of increasing responsibility in corporate development, treasury, financial planning and analysis (FP&A) and investor relations. Prior ...

Core Points - Ashland Inc. plans to release its third-quarter fiscal 2025 earnings on July 29, 2025, at approximately 5 p.m. ET [1] - A live webcast with securities analysts will occur on July 30, 2025, at 10 a.m. ET, featuring an executive summary and detailed remarks [1] - The webcast and supporting materials will be available on Ashland's Investor Relations website, with an archived version accessible for 12 months post-event [3] Company Overview - Ashland Inc. is a global additives and specialty ingredients company focused on environmental, social, and governance (ESG) initiatives [4] - The company serves various markets, including architectural coatings, construction, energy, food and beverage, personal care, and pharmaceuticals [4] - Ashland employs approximately 2,960 professionals, including scientists, research chemists, engineers, and plant operators, dedicated to providing innovative solutions [4]